SCHEMBL4881015

SCHEMBL4881015

COC(=O)CCCCOc1cc(C2=NOC3(CCCC3)C2)ccc1OC

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 7/20 0.47
PDE4A P27815 6/20 0.47
PDE4C Q08493 6/20 0.47
PDE4D Q08499 6/20 0.47
MAPT P10636 1/20 0.40
HDAC1 Q13547 1/20 0.39
HDAC2 Q92769 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
MIF P14174 2/20 0.39
DHFR P00374 2/20 0.39
F2 P00734 5/20 0.39
F10 P00742 5/20 0.39
PRSS1 P07477 4/20 0.39
ALDH1A1 P00352 1/20 0.37
ITGB1 P05556 1/20 0.36
ITGA4 P13612 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4878067 0.99 PDE4A (0.46) PDE4BPDE4APDE4CPDE4DMAPT
SCHEMBL4871255 0.98 PDE4B (0.47) PDE4BPDE4APDE4CPDE4DMAPT
SCHEMBL4870163 0.85 PDE4B (0.44) PDE4BPDE4APDE4CPDE4DMIF
SCHEMBL5246029 0.83 PDE4B (0.46) PDE4BPDE4APDE4CPDE4DMIF
SCHEMBL4867717 0.83 PDE4B (0.48) PDE4BPDE4APDE4CPDE4DHDAC1
SCHEMBL4876107 0.83 PDE4B (0.41) PDE4BPDE4APDE4CPDE4DMIF
SCHEMBL4867637 0.83 PDE4B (0.48) PDE4BPDE4APDE4CPDE4DMIF
SCHEMBL5244019 0.82 PDE4B (0.43) PDE4BPDE4APDE4CPDE4DMAPT
SCHEMBL4877912 0.82 PDE4B (0.48) PDE4BPDE4APDE4CPDE4DMAPT
SCHEMBL4877799 0.82 PDE4B (0.47) PDE4BPDE4APDE4CPDE4DMIF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080009535-A1 Inhibitors of phosphodiesterase type-IV RANBAXY LABORATORIES LIMITED (IN) 2008-01-10 US claimed
EP-1840123-A1 Isoxazolines and their use as inhibitors of phosphodiesterase type-IV Ranbaxy Laboratories Limited (IN) 2007-10-03 EP claimed
US-20080009535-A1 Inhibitors of phosphodiesterase type-IV RANBAXY LABORATORIES LIMITED (IN) 2008-01-10 US disclosed
EP-1840123-A1 Isoxazolines and their use as inhibitors of phosphodiesterase type-IV Ranbaxy Laboratories Limited (IN) 2007-10-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080009535-A1 Inhibitors of phosphodiesterase type-IV PDE4A, PDE3B, PDE4B PDE4B 3/4885PDE4A 1/4885PDE4C 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.